Última actualización 3 de septiembre de 2026
Key finding
The adjusted mean percent change from baseline in UACR for tirzepatide 5 mg compared with all pooled comparators was -19.3% (95% CI -25.5, -12.5).
The study evaluated the effects of tirzepatide on urine albumin-to-creatinine ratio in adults with type 2 diabetes and high cardiovascular risk, finding significant reductions across all doses.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of tirzepatide on urine albumin-to-creatinine ratio in adults with type 2 diabetes and high cardiovascular risk, finding significant reductions across all doses.
This study is important as it highlights the potential of tirzepatide to improve kidney health in patients with type 2 diabetes, a group at high risk for kidney complications. Reducing urine albumin levels can indicate better kidney function and lower cardiovascular risk, making tirzepatide a valuable treatment option.
Effectiveness of tirzepatide remains unclear due to lack of statistical significance. No differences in eGFR were observed, limiting conclusions about kidney function. The study may have limited generalizability due to specific population characteristics.
Published in
Publication details and source links for this paper.
Ellen MA, Katherine RT, Imre P, et al. Tirzepatide Reduces Urine Albumin-to-Creatinine Ratio in Adults with Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care. 2025;48(3):430-436. doi:10.2337/dc24-1773
Tirzepatide 5 mg reduced UACR by -19.3% (95% CI -25.5, -12.5).
Tirzepatide 10 mg reduced UACR by -22.0% (95% CI -28.1, -15.3).
Tirzepatide 15 mg reduced UACR by -26.3% (95% CI -32.0, -20.0).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Tirzepatide and Estimated glomerular filtration rate, Urinary albumin-to-creatinine ratio.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
2
Evidence pairs
100
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Intervención
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Tirzepatide → Estimated glomerular filtration rate
Tirzepatide → Estimated glomerular filtration rate
Tirzepatide → Urinary albumin-to-creatinine ratio
Tirzepatide → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Kidney Function, GLP-1 Receptor Agonists and Kidney Function.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Kidney Function
Measures Kidney Function as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve kidney function.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Estimated glomerular filtration rate
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Urinary albumin-to-creatinine ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
